This study is to assess the impact of two skincare regimens on the cutaneous microbiome and skin physiology of healthy male and female infants, ages 3-6 months using clinical, instrumental, D-Squame tape, microbiome and parental assessments over a five-week period.

Skin cleansing has been demonstrated as a simple strategy to help keep skin healthy. There are many types of cleansing and moisturizing routines that have been shown to have different effects on the skin barrier such as reducing sebum and exogenous contaminants, controlling odors, and affecting the skin microbiome.1 A previous study in an adult population showed that use of a mild surfactant cleanser had less of an impact on the skin barrier than a liquid castile soap (data on file ).2 Because infant skin differs from an adult's in structure, function, and composition3, cleanser and/or lotion regimens may impact the skin barrier of infants differently.

There is very little information in the literature on how the use of product regimens impacts the cutaneous microbiome and skin physiology of adults1 and even less about how it impacts the skin of children.

This study will explore the impact that the use of two regimens - one cleansing and the other cleansing and moisturizing - has on the holistic skin barrier of infants ages 3-6 months.

The IPs are a baby wash and a baby lotion, which are both cosmetic body products. The auxiliary product is a commercially available, cosmetic baby body wash.

Inclusion Criteria:

• Male or Female
• 3 - 6 months old (up to but not including 7 months, 0 days)
• Generally in good health based on medical history reported by the subject's parent/LAR.
• Parent/LAR Is 18 years of age or older and willing/able to present proof of guardianship for the infant subject (i.e., birth certificate, hospital records, adoption record, insurance card, other ID along with valid ID of parent/LAR).
• Parent/LAR has signed the ICD including Health Insurance Portability and Accountability Act (HIPAA) disclosure in English, for the infant to participate in the study.
• Parent/LAR agrees not to introduce any new products or fragrances on his/her person, on his/her infant (e.g. cleansers, lotions, perfumes, etc.), or in the household environment that the infant may come in contact with (e.g. room fresheners, cleansing agents, etc.) for the duration of the study other than the product provided.
• Parent/LAR agrees to limit subject's sun exposure and to use appropriate sun protection including clothing, hats and shade as appropriate. Subject's own sunscreen may be used at the parent's/LAR's discretion on exposed areas, but use should be documented. Parent/LAR should make every effort to limit the subject's sun exposure for the duration of the study.
• Parent/LAR is willing and able to participate in and comply with the study requirements including using the investigational study materials as directed on his/her infant throughout the study period.
• Parent/LAR agrees not to use the provided products on self or any family member other than the infant subject.
• Parent/LAR agrees to not allow their infant to participate in another clinical study or product use study during the study duration.
• Parent/LAR agrees to the possible subsequent use of the data in medical or scientific journals and medical or scientific presentation materials and advertising materials. All subject identities will remain confidential.

Exclusion Criteria

• Has known allergies, adverse reactions, or unusual hypersensitivity to common topical skincare products or their components, fragrances, skin care toiletry products or adhesive tapes.

• Presents with a skin condition that may influence the outcome of the study (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, active skin cancer, sensitive skin, moderate to severe looking diaper rash).

• Actively taking any medications, particularly antibiotics either oral or topical, as they may interfere with the study. Any condition requiring use of a topical or oral OTC or prescription medication, which in the Study Physician's judgement makes the subject ineligible or places the subject at risk (e.g. antibiotics such as Amoxicillin, Zithromax, Cefphalexin or any other medications that may cause gastrointestinal distress/diarrhea that will affect skin condition/cause irritation/rash of genital/buttocks area).

• Infant may not swim, or use hot tubs or pools for the duration of the study.

• Has Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication as reported by the parent/LAR.

• Has taken medications that would mask an AE or influence the study results, including:

  • Immunosuppressive drugs and steroidal and/or non-steroidal anti-inflammatory drugs within 3 months before Visit 1 and during the study.
  • Antihistamines within 1 month before Visit 1 and during the study.
  • Receiving systemic or topical medications, which may interfere with study evaluations.
  • Has a history of or a concurrent health condition/situation, which, in the opinion of the PI or Study Physician, may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study.

• Is simultaneously participating in any other type of clinical study or product use study

• Has had a recent change in dietary intake within 1 week (7 days) prior to study start.

• Has a known condition of asthma or any related breathing problem and/or for whom there is a family history of asthma.

• Has an active localized or general infections including upper respiratory infections (ear, nose, throat, fever, cough, etc.).

• Has excessive scars, which could interfere with expert grader evaluations.

• Is viewed by the PI or Study Physician as not being able to complete the study.

• Parent/LAR is pregnant and/or planning to become pregnant during the study or within the next 3 months.

This study will be evaluator-blinded, so the PI/expert graders will not know which group (Group 1 or Group 2) each subject is in. Personnel dispensing the IPs or supervising IP use will not participate in the evaluation of subjects in order to minimize potential bias. IPs will be kept separate from the site personnel involved in assessing or evaluating the subjects, and subjects will be instructed not to discuss their assigned IPs with the PI/expert graders or other subjects.

To keep the evaluator blinded, the study staff will keep the grading forms separate from the bulk of the source documents so the evaluator will not have access to the sheets that indicate randomization and the study staff will instruct the subjects/LAR to not say anything about what product they are using.